Size | Price | Stock | Qty |
---|---|---|---|
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
Purity: ≥98%
Esomeprazole Sodium (formerly 18-sodium; H199; 18 sodium; H-199; Nexium IV; S-Omeprazole sodium), the sodium salt of esomeprazole, is the S-isomer of omeprazole which is a potent PPI-proton pump inhibitor with an IC50 of 0.076 mg/kg. Esomeprazole Sodium has been approved for the short-term treatment of gastroesophageal reflux disease-GERD.
ln Vitro |
Esomeprazole (25-100 µM; 20 hours; MDA-MB-468 cells) treatment enhances intracellular acidification, which in turn suppresses the development of triple-negative breast cancer cells in vitro in a dose-dependent way [1].
|
---|---|
ln Vivo |
The advancement of pulmonary fibrosis in C57BL/6J mice was markedly slowed down by treatment with esomeprazole (30–300 mg/kg; oral gavage; daily; for 19 or 11 days). Furthermore, esomeprazole lowers circulating indicators of fibrosis and inflammation [2].
|
Cell Assay |
Cell Viability Assay[1]
Cell Types: MDA-MB-468 Cell Tested Concentrations: 25 µM, 50 µM, 75 µM, 100 µM Incubation Duration: 20 hrs (hours) Experimental Results: Inhibition of triple negative breast cancer cells in a dose-dependent manner in vitro. |
Animal Protocol |
Animal/Disease Models: C57BL/6J mice (8 weeks old, 25-30 g) cotton smoke-induced lung injury [2]
Doses: 30 mg/kg, 300 mg/kg Route of Administration: po (oral gavage); daily; continued for 19 Or 11-day Experimental Results: Dramatically inhibited the progression of lung fibrosis in animals. |
References |
[1]. Wayne Goh, et al. Use of proton pump inhibitors as adjunct treatment for triple-negative breast cancers. An introductory study. J Pharm Pharm Sci. 2014;17(3):439-46.
[2]. Christina Nelson, et al. Therapeutic Efficacy of Esomeprazole in Cotton Smoke-Induced Lung Injury Model. Front Pharmacol. 2017 Jan 26;8:16. [3]. Thomas J Johnson, et al. Esomeprazole: a clinical review. Am J Health Syst Pharm. 2002 Jul 15;59(14):1333-9. [4]. Huarui Zhang, et al. Advances in the discovery of exosome inhibitors in cancer. J Enzyme Inhib Med Chem. 2020 Dec;35(1):1322-1330. |
Molecular Formula |
C17H18N3O3S.NA
|
|
---|---|---|
Molecular Weight |
367.4
|
|
CAS # |
161796-78-7
|
|
Related CAS # |
Esomeprazole;119141-88-7;Esomeprazole magnesium trihydrate;217087-09-7;Esomeprazole magnesium;161973-10-0;Esomeprazole magnesium salt;1198768-91-0;Esomeprazole potassium salt;161796-84-5;Esomeprazole hemistrontium;914613-86-8;Esomeprazole-d6 sodium;922731-04-2
|
|
SMILES |
S(C1=NC2C([H])=C([H])C(=C([H])C=2N1[H])OC([H])([H])[H])(C([H])([H])C1C(C([H])([H])[H])=C(C(C([H])([H])[H])=C([H])N=1)OC([H])([H])[H])=O.[Na] |^1:43|
|
|
InChi Key |
RYXPMWYHEBGTRV-JIDHJSLPSA-N
|
|
InChi Code |
InChI=1S/C17H18N3O3S.Na/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17;/h5-8H,9H2,1-4H3;/q-1;+1/t24-;/m0./s1
|
|
Chemical Name |
sodium (S)-5-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide
|
|
Synonyms |
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.7218 mL | 13.6091 mL | 27.2183 mL | |
5 mM | 0.5444 mL | 2.7218 mL | 5.4437 mL | |
10 mM | 0.2722 mL | 1.3609 mL | 2.7218 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.